Paroxetine overdose during pregnancy

• Published in: Forensic sciences research Vol. 6; no. 3; pp. 237 - 239
• Main Authors: Acar, Selin, Erol, Hilal, Arslan, Elif Keskin, Uysal, Nusret, Karadaş, Barış, Temiz, Tijen Kaya, Cem Kaplan, Yusuf
• Format: Journal Article
• Language: English
• Published: Abingdon Taylor & Francis Ltd 03.07.2021; Taylor & Francis; Oxford University Press
• Subjects: Antidepressants; Anxiety; Anxiety disorders; Case Report; Case reports; Citalopram; Congenital defects; Congenital diseases; Developmental disabilities; Drug overdose; Epidemiology; Fetuses; Forensic sciences; forensic toxicology; Intoxication; Mental depression; Overdose; Paroxetine; Patients; Pregnancy; Risk assessment; Serotonin uptake inhibitors; Suicide; teratogenicity
• ISSN: 2096-1790; 2471-1411
• DOI: 10.1080/20961790.2021.1938802

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression and anxiety disorders. In some epidemiological studies, slightly increased risks of major malformations and cardiac malformations have been reported following paroxetine exposure in the first trimester of pregnancy. However, such findings have been inconsistent. There is only one report of any overdose of an SSRI during pregnancy, and that involved escitalopram. The aim of this case report was to describe the impact of a paroxetine overdose in the first trimester of pregnancy on the health of the foetus. A 21-year-old mother of one child who was pregnant with a second child was prescribed 20 mg/day paroxetine hydrochloride for the treatment of anxiety/depression. The patient ingested 15 or 16 20-mg tablets of paroxetine hydrochloride (300–320 mg) during the 5th week of pregnancy as a suicide attempt. Within 15 min of ingestion, she was admitted to hospital and treated for intoxication. No evidence of maternal SSRI intoxication was observed after treatment. The patient consulted our teratology information service for further risk assessment regarding possible major congenital malformations following the paroxetine overdose. We were unable to find previous reports of paroxetine overdose during pregnancy in the literature. The timely administration of the overdose treatment and the lack of maternal intoxication symptoms were considered positive for the foetal well-being, and the patient was referred for perinatology and psychiatry follow-ups. A healthy, 3 500-g male infant was born at 38 weeks’ gestation, and his development at the age of 2 years was normal. This is the first reported case of paroxetine overdose during pregnancy. Comprehensive studies are needed to evaluate pregnancy outcomes after SSRI overdose.Key PointsThere are no reported data on paroxetine overdose during pregnancy.The aim of this case report was to describe the impact of a maternal paroxetine overdose in the first trimester of pregnancy on the health of the foetus. No evidence of maternal SSRI intoxication was observed.No congenital malformations or developmental disorders were observed in the child at 2 years of age.Comprehensive studies are needed to evaluate pregnancy outcomes following SSRI overdose.